1. Multisite study of the relationships between antemortem [
- Author
-
Renaud, La Joie, Nagehan, Ayakta, William W, Seeley, Ewa, Borys, Adam L, Boxer, Charles, DeCarli, Vincent, Doré, Lea T, Grinberg, Eric, Huang, Ji-Hye, Hwang, Milos D, Ikonomovic, Clifford, Jack, William J, Jagust, Lee-Way, Jin, William E, Klunk, Julia, Kofler, Orit H, Lesman-Segev, Samuel N, Lockhart, Val J, Lowe, Colin L, Masters, Chester A, Mathis, Catriona L, McLean, Bruce L, Miller, Daniel, Mungas, James P, O'Neil, John M, Olichney, Joseph E, Parisi, Ronald C, Petersen, Howard J, Rosen, Christopher C, Rowe, Salvatore, Spina, Prashanthi, Vemuri, Victor L, Villemagne, Melissa E, Murray, and Gil D, Rabinovici
- Subjects
Male ,Thiazoles ,Aniline Compounds ,Alzheimer Disease ,Positron-Emission Tomography ,Humans ,Female ,Plaque, Amyloid ,Autopsy ,Neuropathology ,Article ,Aged ,Retrospective Studies - Abstract
INTRODUCTION: We sought to establish the relationships between standard post mortem measures of AD neuropathology and ante mortem [(11)C]PIB-PET analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. METHODS: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data and autopsy findings. RESULTS: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques, 92 CL for frequent plaques) and non-linearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. Findings were comparable across sites and when restricted to 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (AUC=0.910, Sensitivity=89.2%, Specificity=86.4%) while 24.4 CL identified intermediate-to-high AD neuropathological changes (AUC=0.894, Sensitivity=84.1%, Specificity=87.9%). DISCUSSION: Our study demonstrated the robustness of a multi-site Centiloid [(11)C]PIBPET study and established a range of pathology-based CL thresholds.
- Published
- 2018